🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Cologne
Clinical trial register · Germany

Clinical Trials in Cologne, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca48 Novartis Pharmaceuticals29 University of Cologne25 Janssen Research & Development, LLC21 Bristol-Myers Squibb21
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Cologne

612 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
Investigation of the Audible ICD Alert Tone
NCT06388382Implantable Defibrillator User
Universitätsklinikum Köln
Observational
150
Cologne
2024-10-01
Active, closed
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
DrugsDivarasib·Adagrasib·Sotorasib
Hoffmann-La Roche
Phase 3
338
Berlin, Cologne, Essen, Esslingen am Neckar, Gauting, Großhansdorf, Heidelberg, Hemer
2024-09-23
Active, closed
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
NCT06559163Systemic Lupus Erythematosus
DrugObexelimab
Zenas BioPharma (USA), LLC
Phase 2
190
München, Cologne
2024-09-17
Recruiting
Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) in Patients With Mild to Moderately Active Ulcerative Colitis
NCT06488625Ulcerative Colitis, Unspecified
University Hospital Schleswig-Holstein
Phase 2/3
459
Kiel, Aachen, Augsburg, Bamberg, Berlin, Bremen, Cologne, Dachau
2024-09-12
Recruiting
Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl
NCT06498349Parkinson Disease, Impulse Control Disorders
University of Kiel
Not applicable
60
Cologne, Dresden, Düsseldorf, Hamburg, Kiel, Marburg, Mitte, Tübingen
2024-09-05
Recruiting
STIMPulseControl Ancillary Speech Study
NCT06561919Parkinson Disease, Impulse Control Disorder
Steffen Paschen
Not applicable
60
Cologne, Dresden, Düsseldorf, Hamburg, Kiel, Marburg, Mitte, Tübingen
2024-09-05
Active, closed
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
NCT06581198Lupus Erythematosus, Systemic, Lupus Nephritis
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
179
Stuttgart, Frankfurt am Main, Cologne, Leipzig, Jena, Essen, Lübeck, Mainz
2024-09-04
Recruiting
ATLAS (AltaValve) Pivotal Trial
NCT06465745Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Incompetence, Mitral Valve Regurgitation
4C Medical Technologies, Inc.
Not applicable
450
Berlin, Bonn, Cologne, Dortmund, Mainz, Oeynhausen, Trier, Ulm
2024-09-03
Recruiting
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
NCT06274801Pulmonary Arterial Hypertension
DrugSeralutinib
Gossamer Bio USA, Inc.
Phase 3
330
Cologne, Dresden, Giessen, Heidelberg, Munich, München, Würzburg
2024-09-03
Not yet open
Exercise Intervention in Women Diagnosed With Triple-negative Breast Cancer Receiving Oncologic Treatment
NCT06497322Breast Cancer, Triple Negative Breast Cancer
University Hospital of Cologne
Not applicable
60
Cologne
2024-09-01
Recruiting
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation
DrugsSevabertinib·Pemetrexed·Cisplatin·Carboplatin
Bayer
Phase 3
555
Stuttgart, Nuremberg, Frankfurt am Main, Giessen, Cologne, Essen, Hemer, Berlin
2024-08-28
Active, closed
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT06413498Multiple Myeloma
DrugsAnitocabtagene Autoleucel·Carfilzomib·Pomalidomide·Bortezomib
Kite, A Gilead Company
Phase 3
452
Berlin, Cologne, Essen, Freiburg im Breisgau, Hamburg, Leipzig, München, Tübingen
2024-08-23
Recruiting
Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma
NCT06440993Extrahepatic Cholangiocarcinoma, Unresectable Perihilar or Ductal CCA
DrugsDurvalumab·Gemcitabine·Cisplatin
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
42
Aachen, Bonn, Cologne, Düsseldorf, Frankfurt, Göttingen, Hanover, Lübeck
2024-08-23
Recruiting
Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL
NCT05583071Non-Hodgkin Lymphoma
DrugsTafasitamab·Methotrexate·Lenalidomide·Rituximab
University of Cologne
Phase 2
20
Stuttgart, Freiburg im Breisgau, Cologne, Hamburg, Essen, Berlin
2024-08-23
Recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
DrugsVolrustomig·Adrucil·Paclitaxel·Cisplatin
AstraZeneca
Phase 2
257
Cologne, Frankfurt, Gauting, Großhansdorf, Hamburg, Heidelberg, Mainz, Münster
2024-08-22
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
DrugZilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 1/2
90
Tübingen, Cologne, Münster, Berlin
2024-08-16
Recruiting
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
NCT06467357Biliary Tract Cancer
DrugsRilvegostomig·Trastuzumab deruxtecan·Durvalumab·Gemcitabine
AstraZeneca
Phase 3
620
Berlin, Bonn, Cologne, Dresden, Frankfurt, Freiburg im Breisgau, Göttingen, Hamburg
2024-08-12
Active, closed
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
NCT06534892Respiratory Syncytial Virus Infections
DrugRSVPreF3 OA vaccine
GlaxoSmithKline
Phase 3
10,212
Weinheim, Munich, Freiberg, Berlin, Cologne, Dachau, Dippoldiswalde, Dresden
2024-08-01
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751Advanced Breast Cancer
DrugsSaruparib·Camizestrant·Exemestane·Anastrozole
AstraZeneca
Phase 3
788
Aachen, Augsburg, Berlin, Cologne, Dessau, Düsseldorf, Erlangen, Göttingen
2024-08-01
Recruiting
HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life
NCT05373264ADPKD
DrugHydrochlorothiazide
University Medical Center Groningen
Phase 3
300
Berlin, Cologne, Dresden, Leipzig
2024-07-31
Active, closed
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
NCT06544616Alzheimer Disease
Janssen Pharmaceutica N.V., Belgium
Phase 2
55
Aachen, Cologne, Homburg, Münster
2024-07-22
Active, closed
Chronic Limb-Threatening Ischemia Treated With Intravascular Lithotripsy Observational Study
NCT06149650Chronic Limb-Threatening Ischemia
Cardiovascular and Interventional Radiological Society of Europe
Observational
400
Cologne, Essen, Hanover, Heilbronn, Karlsruhe, Mülheim, Neumünster, Rendsburg
2024-07-15
Recruiting
NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations
NCT06494540Non-squamous Metastatic Non-Small-Cell Lung Carcinoma
AstraZeneca
Observational
600
Bad Homburg, Berlin, Bremen, Celle, Chemnitz, Cologne, Deggendorf, Frankfurt
2024-06-28
Active, closed
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
NCT06118281Cardiovascular Risk, Acute Myocardial Infarction (AMI)
DrugZiltivekimab
Novo Nordisk A/S
Phase 3
10,000
Bad Berka, Berlin, Bielefeld, Bremen, Cologne, Dachau, Dortmund, Dresden
2024-06-25
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
Würzburg, Frankfurt am Main, Hanover, Aachen, Cologne, Mainz, Homburg, Berlin
2024-06-25
Active, closed
Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
NCT06455059Hypochondroplasia
DrugVosoritide
BioMarin Pharmaceutical
Phase 3
80
Cologne, Magdeburg
2024-06-17
Active, closed
Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06223516Multiple Myeloma
DrugEtentamig
AbbVie
Phase 1
60
Frankfurt am Main, Cologne, Hamburg
2024-06-17
Recruiting
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
NCT06303505Ovarian Cancer, Non-small Cell Lung Cancer
DrugTUB-040
Tubulis GmbH
Phase 1/2
250
Berlin, Cologne
2024-06-12
Active, closed
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
DrugsTarlatamab·Durvalumab
Amgen
Phase 3
563
Cologne, Dresden, Essen, Gauting, Großhansdorf, Heidelberg, Münster, Würzburg
2024-06-05
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801Crohn's Disease
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 3
1,200
Pforzheim, München, Ulm, Hanover, Lüneburg, Rostock, Cologne, Duisburg
2024-06-05
Recruiting
Next-Generation-Sequencing Approach to Neutropenic Sepsis
NCT05815628Febrile Neutropenia
Boris Böll
Observational
400
Cologne, Dessau, Essen, Frankfurt am Main, Leipzig, Magdeburg
2024-06-05
Recruiting
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
NCT06439277Obesity, Weight Gain
DrugTirzepatide
Eli Lilly and Company
Phase 3
300
Cologne, Leipzig, Ulm
2024-06-03
Recruiting
Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma
NCT04837859Classical Hodgkin Lymphoma
DrugTislelizumab
University of Cologne
Phase 2
120
Cologne
2024-05-24
Recruiting
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972Systemic Lupus Erythematosus
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
550
Cologne, Leipzig
2024-05-21
Recruiting
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
Vedanta Biosciences, Inc.
Phase 3
852
Frankfurt am Main, Cologne, Berlin
2024-05-20
Active, closed
A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis
NCT06294925Colitis, Ulcerative
DrugEtrasimod
Pfizer
Observational
360
Freiburg im Breisgau, Kassel, Aachen, Andernach, Berlin, Cologne, Dachau, Frankfurt am Main
2024-05-08
Recruiting
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
NCT06508775Melanoma Stage III, B-cell Non Hodgkin Lymphoma, Pediatric ALL, Childhood Non-Hodgkin Lymphoma
DrugsMB-CART19.1·Zamtocabtagene autoleucel
Miltenyi Biomedicine GmbH
Not applicable
40
Berlin, Cologne, Erlangen, Göttingen, Münster, Tübingen, Würzburg
2024-05-05
Recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097Non-small Cell Lung Cancer
DrugsDatopotamab deruxtecan·Osimertinib
AstraZeneca
Phase 3
582
Berlin, Cologne, Erfurt, Frankfurt, Göttingen, Immenhausen, Kiel, Mainz
2024-04-29
Active, closed
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
NCT05972551Osteogenesis Imperfecta
DrugRomosozumab
Amgen
Phase 3
111
Cologne, Würzburg
2024-04-22
Recruiting
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820Non-Muscle Invasive Bladder Neoplasms
DrugGemcitabine
Janssen Research & Development, LLC
Phase 3
641
Berlin, Braunschweig, Cologne, Dresden, Frankfurt am Main, Hamburg, Herne, Jena
2024-04-18
Recruiting
European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]
NCT06137378Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma Stage III, Laryngeal Squamous Cell Carcinoma Stage IV
DrugsKeytruda·Pembrolizumab
University of Leipzig
Phase 2
140
Mannheim, Ulm, München, Regensburg, Würzburg, Potsdam, Cologne, Leipzig
2024-04-17
Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533Non-Small Cell Lung Cancer
DrugsRilvegostomig·Datopotamab deruxtecan·Keytruda·Pembrolizumab
AstraZeneca
Phase 3
675
Berlin, Bonn, Cologne, Düsseldorf, Essen, Freiburg im Breisgau, Gauting, Georgsmarienhütte
2024-04-11
Recruiting
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
NCT05791409CLL/SLL
DrugsEpcoritamab·Venetoclax
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 1/2
112
Berlin, Cologne, Freiburg im Breisgau, Greifswald, Münster, Stuttgart, Ulm
2024-04-10
Recruiting
Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma
NCT05871021Glioblastoma
University Hospital Tuebingen
Phase 2
146
Augsburg, Cologne, Frankfurt, Freiburg im Breisgau, Leipzig, Mannheim, Munich, Regensburg
2024-04-10
Active, closed
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
NCT06211764Non-Muscle Invasive Bladder Neoplasms
DrugsTAR-200·Mitomycin C·Gemcitabine
Janssen Research & Development, LLC
Phase 3
272
Cologne, Halle, Leverkusen, Lübeck, Mettmann, München
2024-04-09
Recruiting
Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML
NCT05904106Acute Myeloid Leukemia
DrugsGemtuzumab Ozogamicin·Azacitidine·Venetoclax
Technische Universität Dresden
Phase 2
146
Essen, Aachen, Augsburg, Chemnitz, Cologne, Dresden, Erlangen, Frankfurt am Main
2024-04-07
Recruiting
A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies
NCT06274515Breast Cancer
Hoffmann-La Roche
Phase 4
320
Cologne, Essen, Karlsruhe, Mannheim, Ulm
2024-04-02
Active, closed
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy
NCT06333808HIV-1-infection
DrugsBictegravir·Lenacapavir·B/F/TAF
Gilead Sciences
Phase 3
577
Aachen, Berlin, Cologne, Frankfurt, Hamburg, Munich, München
2024-03-25
Recruiting
Phase 3 Clinical Trial with Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients
NCT05944016Chronic Kidney Failure in Children and Young Adults
DrugDapagliflozin
University Hospital Goettingen
Phase 3
102
Heidelberg, München, Hamburg, Frankfurt am Main, Göttingen, Cologne, Münster, Leipzig
2024-03-25
Recruiting
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
NCT05904119First Progression of Glioblastoma
DrugLomustine
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
411
Bochum, Cologne, Erlangen, Essen, Heidelberg, Leipzig, Munich, Regensburg
2024-03-15
By invitation
ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation
NCT05932615Aortic Valve Stenosis, Heart Valve Diseases, Aortic Valve Disease, Heart Disease Structural Disorder
Abbott Medical Devices
Not applicable
1,500
Dortmund, Bad Nauheim, Cologne, Frankfurt, Kiel, München, Ulm
2024-03-15
Recruiting
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
NCT05939414Oligometastatic Prostate Cancer (OMPC)
DrugsPiflufolastat·Lu-PSMA
Novartis Pharmaceuticals
Phase 3
450
Munich, Cologne, Aachen, Augsburg, Berlin, Essen, Münster, Rostock
2024-03-12
Recruiting
Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma
NCT04838652Classical Hodgkin Lymphoma
DrugPembrolizumab
University of Cologne
Phase 2
29
Cologne
2024-03-05
Active, closed
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
DrugLepodisiran
Eli Lilly and Company
Phase 3
17,300
Aachen, Bad Friedrichshall, Bad Homburg, Berlin, Bielefeld, Cologne, Dresden, Essen
2024-03-05
Active, closed
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
NCT06335173Alzheimer Disease
Acumen Pharmaceuticals
Phase 2
542
Berlin, Cologne, Mannheim, Munich
2024-02-29
Active, closed
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)
NCT05925530Non-small Cell Lung Cancer
DrugDurvalumab
AstraZeneca
Phase 2
142
Berlin, Cologne, Großhansdorf, Moers, Würzburg
2024-02-22
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
NCT05979311HIV, HIV Infections
DrugsBictegravir·Emtricitabine·Dolutegravir·Lamivudine
ViiV Healthcare
Phase 3
307
Berlin, Cologne, Frankfurt, Hamburg, München
2024-02-21
Active, closed
Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)
NCT06380738Metastatic Castration-resistant Prostate Cancer
AstraZeneca
Observational
111
Aschaffenburg, Augsburg, Bergisch Gladbach, Berlin, Bonn, Cologne, Dresden, Duisburg
2024-02-14
Active, closed
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574Lung Cancer, Non-squamous, Non-small Cell
DrugsZongertinib·Pemetrexed·Keytruda·Cisplatin
Boehringer Ingelheim
Phase 3
428
Augsburg, Berlin, Cologne, Dresden, Giessen, Heidelberg, Oldenburg, Tübingen
2024-02-09
Recruiting
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
NCT05902169Glioblastoma, Recurrent Glioblastoma, GBM
DrugsTemodal·Lomustine·Temozolomide·Carboplatin
CarThera
Phase 3
560
Berlin, Chemnitz, Cologne, Dresden, Essen, Münster
2024-01-29
Recruiting
Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS
NCT06553625Parkinson Disease, Dystonia, Essential Tremor, Movement Disorders
Boston Scientific Corporation
Observational
200
Cologne, Düsseldorf, Würzburg
2024-01-29
Active, closed
Early Genetic Identification of Obesity
NCT06239064Obesity, Childhood, Hyperphagia, Retinopathy, Syndactyly
Rolfs Consulting und Verwaltungs-GmbH (RCV)
Observational
1,000
Aachen, Augsburg, Bad Krozingen, Bielefeld, Bonn, Bückeburg, Cologne, Essen
2024-01-24
Active, closed
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
NCT06143891Chronic Graft Versus Host Disease
DrugsBelumosudil·Prednisolone·Prednisone
Sanofi
Phase 3
260
Berlin, Cologne, Dresden, Freiburg im Breisgau, Hamburg, Kiel, Münster, Regensburg
2024-01-23
Recruiting
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06153251Relapsed and/or Refractory Multiple Myeloma
DrugsFludara·Cytoxan·Fludarabine·Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
187
Cologne, Heidelberg, Würzburg
2024-01-23
Recruiting
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
NCT06079398Achondroplasia
DrugNavepegritide
Ascendis Pharma A/S
Phase 2
72
Berlin, Cologne
2024-01-23
Recruiting
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
NCT06137144Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)
DrugsAZD3470·Pembrolizumab
AstraZeneca
Phase 1/2
161
Berlin, Cologne, Erlangen, Würzburg
2024-01-23
Active, closed
Radioimmunotherapy With Lu-177 Labeled 6A10 Fab-fragments in Patients With Glioblastoma After Standard Treatment
NCT05533242Glioblastom WHO Grade 4
University Hospital Muenster
Phase 1
10
Cologne, Essen, Münster, Würzburg
2024-01-22
Active, closed
Modification of Coronary Calcium With Laser Based Intravascular Lithotripsy for Coronary Artery Disease (FRACTURE)
NCT06181240Coronary Artery Disease, Coronary Artery Calcification
Bolt Medical
Not applicable
426
Bad Segeberg, Cologne, Dortmund
2024-01-19
Active, closed
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
NCT06018337Metastatic Breast Cancer
DrugsDB-1303/BNT323·Nab-paclitaxel·Capecitabine·Paclitaxel
DualityBio Inc.
Phase 3
541
Erlangen, Wiesbaden, Bottrop, Cologne, Witten, Dresden, Berlin
2024-01-18
Recruiting
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
DrugsElironrasib·RMC-9805·Cetuximab·Pemetrexed
Revolution Medicines, Inc.
Phase 1/2
616
Berlin, Cologne, Dresden, Frankfurt am Main, Heidelberg, Immenhausen, Moers
2024-01-18
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
DrugALXN2220
Alexion Pharmaceuticals, Inc.
Phase 3
1,181
Berlin, Cologne, Essen, Giessen, Hamburg, Hanover, Heidelberg, Homburg
2024-01-11
Recruiting
Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)
NCT05949125Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
AvenCell Europe GmbH
Phase 1
37
Ulm, Munich, Würzburg, Marburg, Dresden, Berlin, Cologne, Essen
2024-01-03
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Berlin, Cologne, Düsseldorf, Essen, Frankfurt, Freiburg im Breisgau, Halle, Hamburg
2023-12-29
Active, closed
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
NCT06140836Carcinoma, Non-Small-Cell Lung
DrugsRepotrectinib·Crizotinib
Bristol-Myers Squibb
Phase 3
190
Esslingen am Neckar, Würzburg, Oldenburg, Berlin, Cologne, Dresden, Gauting, Immenhausen
2023-12-21
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
DrugsOlomorasib·Pemetrexed·Cisplatin·Carboplatin
Eli Lilly and Company
Phase 3
1,264
Berlin, Chemnitz, Cologne, Donauwörth, Erfurt, Freiburg im Breisgau, Gauting, Georgsmarienhütte
2023-12-21
Recruiting
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
NCT05512364ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
DrugsElacestrant·Tamoxifen·Exemestane·Anastrozole
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
220
Aachen, Augsburg, Bergisch Gladbach, Bottrop, Bremen, Cologne, Dresden, Hanover
2023-12-15
Active, closed
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
DrugsGiredestrant·Ribociclib·Abemaciclib·Palbociclib
Hoffmann-La Roche
Phase 3
1,050
Bamberg, Cologne, Düsseldorf, Erlangen, Essen, Freiburg im Breisgau, Heidelberg, Homburg/Saar
2023-12-11
Active, closed
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
NCT06007690Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
DrugBel-sar
Aura Biosciences
Phase 3
108
Berlin, Cologne, Essen, Hamburg, Lübeck, München, Tübingen
2023-12-06
Active, closed
Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma
NCT05689671Non-Small Cell Lung Cancer Metastatic
DrugsAbraxane·Tecentriq·Atezolizumab·Nab-paclitaxel
Nikolaj Frost MD
Phase 4
136
Amberg, Augsburg, Bad Homburg, Berlin, Bielefeld, Cologne, Dresden, Essen
2023-12-06
Active, closed
A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
NCT05993234HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma
DrugTrastuzumab deruxtecan
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Observational
257
Aschaffenburg, Berlin, Cologne, Essen, Göppingen, Hamburg, Hanover, München
2023-12-05
Recruiting
The Viability Control of Human Endothelial Cells Before Keratoplasty (V-CHECK) Study
NCT05847387Corneal Transplant Failure, Corneal Endothelial Cell Loss
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Observational
135
Cologne, Münster
2023-12-01
Recruiting
The Fourth Left Atrial Appendage Occlusion Study
NCT05963698Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism
Hamilton Health Sciences Corporation
Not applicable
4,000
Karlsruhe, Darmstadt, Frankfurt am Main, Rostock, Bad Oeynhausen, Cologne, Kaiserslautern, Leipzig
2023-11-30
Recruiting
A Multicenter Multinational Observational Study of Children With Hypochondroplasia
NCT06212947Hypochondroplasia
BioMarin Pharmaceutical
Observational
400
Cologne, Magdeburg
2023-11-27
Recruiting
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
NCT05948943Lymphatic Malformations
DrugAlpelisib
Novartis Pharmaceuticals
Phase 2/3
232
Freiburg im Breisgau, Mannheim, Cologne, Leipzig, Berlin, Ulm
2023-11-24
Active, closed
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491Metastatic Castration-Sensitive Prostate Cancer
DrugsSaruparib·Zytiga·Xtandi·Abiraterone acetate
AstraZeneca
Phase 3
1,898
Bergisch Gladbach, Berlin, Braunschweig, Cologne, Dresden, Duisburg, Frankfurt, Frankfurt am Main
2023-11-21
Recruiting
Pretreatment to Promote Graft Survival After Subsequent High-risk Corneal Transplantation [CrossCornealVision]
NCT05870566Corneal Transplantation
Claus Cursiefen
Not applicable
110
München, Cologne, Düsseldorf, Homburg, Berlin, Freiburg im Breisgau, Rostock
2023-11-20
Active, closed
The PEERLESS II Study
NCT06055920Pulmonary Embolism
Inari Medical
Not applicable
1,200
Augsburg, Bad Krozingen, Berlin, Cologne, Dresden, Düsseldorf, Essen, Frankfurt
2023-11-17
Recruiting
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
NCT06128551Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
DrugsElironrasib·Cetuximab
Revolution Medicines, Inc.
Phase 1/2
534
Cologne, Esslingen am Neckar, Moers, Nuremberg
2023-11-14
Active, closed
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
NCT05870579Breast Cancer
Drugs[177Lu]Lu-NeoB·[68Ga]Ga-NeoB·Ribociclib·Fulvestrant
Novartis Pharmaceuticals
Phase 1
28
Cologne
2023-11-13
Active, closed
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728Unresectable Pleural Mesothelioma
DrugsVolrustomig·Ipilimumab·Pemetrexed·Nivolumab
AstraZeneca
Phase 3
863
Berlin, Bochum, Cologne, Essen, Gauting, Georgsmarienhütte, Großhansdorf, Hamburg
2023-11-09
Active, closed
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
NCT06054555Melanoma
DrugsOpdivo·Nivolumab
Amgen
Phase 3
633
Frankfurt am Main, Marburg, Cologne
2023-11-02
Not yet open
Surveillance After Resection of Oesophageal aNd Gastric Cancer (SARONG-II) Trial
NCT06115629Esophageal Cancer, Gastric Cancer
University of Dublin, Trinity College
Phase 3
952
Cologne
2023-11
Active, closed
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
NCT05987332Metastatic Uveal Melanoma
DrugsDarovasertib·Crizotinib·Dacarbazine·Yervoy
IDEAYA Biosciences
Phase 2/3
420
Heidelberg, Cologne, Essen, Dresden, Berlin
2023-10-31
Active, closed
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
NCT05985915Sjogrens Syndrome
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
612
Freiburg im Breisgau, Würzburg, Ludwigshafen, Cologne, Dresden, Berlin, Erlangen, Hanover
2023-10-27
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578Progressive Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
1,057
Freiburg I. Breisgau, Wangen I. Allgaeu, Munich, Münnerstadt, Immenhausen, Stralsund, Essen, Cologne
2023-10-25
Recruiting
GENERATE - Next GENERATion of GynEcological Surgery - Robotic Assisted Surgery in Gynecological Indications
NCT05867927GYN Disorders
Intuitive Surgical
Observational
1,250
Hamburg, Wiesbaden, Berlin, Bochum, Coburg, Cologne, Essen, Frankfurt am Main
2023-10-25
Active, closed
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
NCT05968326Adenocarcinoma, Pancreatic Ductal
DrugsAutogene Cevumeran·MFOLFIRINOX·Tecentriq·Atezolizumab
Genentech, Inc.
Phase 2
260
Berlin, Bochum, Cologne, Dresden, Essen, Frankfurt, Hamburg, Heidelberg
2023-10-18
Active, closed
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06045806Multiple Myeloma
DrugsIdecabtagene vicleucel·Endoxan·Fludara·Cytoxan
Celgene
Phase 3
79
Heidelberg, Ulm, Nuremberg, Cologne, Leipzig, Dresden, Essen, Hamburg
2023-10-16
Active, closed
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
NCT05257083Multiple Myeloma
DrugsCilta-cel·Bortezomib·Daratumumab·Lenalidomide
Stichting European Myeloma Network
Phase 3
759
Cologne, Hamburg, Leipzig, Tübingen, Würzburg
2023-10-10
Active, closed
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole
AstraZeneca
Phase 3
5,511
Aachen, Berlin, Cologne, Darmstadt, Deggendorf, Dessau, Düsseldorf, Essen
2023-10-05
Rows per page Showing 201–300 of 612
Previous 1 2 3 4 5 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/cologne?page=3

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 612 of those studies with a site in Cologne.

How many clinical trials are recruiting in Cologne?

312 of the 612 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 27 have not yet opened recruitment, 261 are active but closed to new participants, and 12 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.